Wedbush analyst Liana Moussatos reiterated a Hold rating on Regulus (RGLS) today and set a price target of $1.00. The company’s shares closed last Tuesday at $0.53, close to its 52-week low of $0.42.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 5.3% and a 47.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
Regulus has an analyst consensus of Moderate Buy, with a price target consensus of $1.25, representing a 150.0% upside. In a report issued on November 6, Needham also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.74 and a one-year low of $0.42. Currently, Regulus has an average volume of 540.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
